Annexin Pharmaceuticals (Sweden) Performance
| ANNX Stock | SEK 0.50 0.01 1.96% |
The firm shows a Beta (market volatility) of 0.27, which signifies not very significant fluctuations relative to the market. As returns on the market increase, Annexin Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Annexin Pharmaceuticals is expected to be smaller as well. At this point, Annexin Pharmaceuticals has a negative expected return of -0.0084%. Please make sure to confirm Annexin Pharmaceuticals' treynor ratio, value at risk, and the relationship between the total risk alpha and maximum drawdown , to decide if Annexin Pharmaceuticals performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Annexin Pharmaceuticals AB has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable basic indicators, Annexin Pharmaceuticals is not utilizing all of its potentials. The current stock price uproar, may contribute to short-horizon losses for the private investors. ...more
| Begin Period Cash Flow | 18.1 M |
Annexin |
Annexin Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 54.00 in Annexin Pharmaceuticals AB on September 1, 2024 and sell it today you would lose (4.00) from holding Annexin Pharmaceuticals AB or give up 7.41% of portfolio value over 90 days. Annexin Pharmaceuticals AB is generating negative expected returns and assumes 4.7429% volatility on return distribution over the 90 days horizon. Simply put, 42% of stocks are less volatile than Annexin, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Annexin Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Annexin Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Annexin Pharmaceuticals AB, and traders can use it to determine the average amount a Annexin Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0018
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ANNX |
Estimated Market Risk
| 4.74 actual daily | 42 58% of assets are more volatile |
Expected Return
| -0.01 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| 0.0 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Annexin Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Annexin Pharmaceuticals by adding Annexin Pharmaceuticals to a well-diversified portfolio.
Annexin Pharmaceuticals Fundamentals Growth
Annexin Stock prices reflect investors' perceptions of the future prospects and financial health of Annexin Pharmaceuticals, and Annexin Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Annexin Stock performance.
| Return On Equity | -1.06 | |||
| Return On Asset | -0.57 | |||
| Current Valuation | 125.48 M | |||
| Shares Outstanding | 154.5 M | |||
| Price To Book | 4.90 X | |||
| EBITDA | (50.28 M) | |||
| Cash And Equivalents | 22.77 M | |||
| Cash Per Share | 1.29 X | |||
| Debt To Equity | 1.20 % | |||
| Book Value Per Share | 0.20 X | |||
| Cash Flow From Operations | (45.02 M) | |||
| Earnings Per Share | (0.43) X | |||
| Total Asset | 52.79 M | |||
About Annexin Pharmaceuticals Performance
Assessing Annexin Pharmaceuticals' fundamental ratios provides investors with valuable insights into Annexin Pharmaceuticals' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Annexin Pharmaceuticals is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Annexin Pharmaceuticals AB , a biotechnology company, engages in developing drug candidates for the treatment of various cardiovascular diseases. The company was founded in 2014 and is based in Stockholm, Sweden. Annexin Pharmaceuticals is traded on Stockholm Stock Exchange in Sweden.Things to note about Annexin Pharmaceuticals performance evaluation
Checking the ongoing alerts about Annexin Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Annexin Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Annexin Pharmaceuticals generated a negative expected return over the last 90 days | |
| Annexin Pharmaceuticals has some characteristics of a very speculative penny stock | |
| Annexin Pharmaceuticals has high historical volatility and very poor performance | |
| Annexin Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (52.14 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Annexin Pharmaceuticals AB has accumulated about 22.77 M in cash with (45.02 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.29, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 45.0% of the company shares are held by company insiders |
- Analyzing Annexin Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Annexin Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Annexin Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Annexin Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Annexin Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Annexin Pharmaceuticals' stock. These opinions can provide insight into Annexin Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Annexin Stock Analysis
When running Annexin Pharmaceuticals' price analysis, check to measure Annexin Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Annexin Pharmaceuticals is operating at the current time. Most of Annexin Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Annexin Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Annexin Pharmaceuticals' price. Additionally, you may evaluate how the addition of Annexin Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.